FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
about
Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228)Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole.Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs.Identification and characterization of the spiruchostatin biosynthetic gene cluster enable yield improvement by overexpressing a transcriptional activator.Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.Interpreting clinical assays for histone deacetylase inhibitors.Romidepsin in the treatment of cutaneous T-cell lymphoma.Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancerTreating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome.Bicyclic Peptides as Next-Generation Therapeutics.Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection.P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell LinesSynthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffoldA rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.Discovery and mechanism of natural products as modulators of histone acetylation.Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphomaEpigenetic changes in gliomas.Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.Novel therapies for peripheral T-cell lymphomas.Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N-heterocyclic carbene mediated acylations in complex molecule synthesis.Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cellsIn vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells.FK228 from Burkholderia thailandensis MSMB43.The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery.
P2860
Q24633204-AE681E15-7958-4C97-9114-16ABBFC87A46Q33235403-46D98825-936E-47E0-B9B8-4F38C89EAFF9Q33893992-8A36707B-4B89-48C8-8CBA-818A73CB27DBQ33939126-6E2B0C61-E1F9-44EF-998A-E9E29104446AQ34051299-3B132C28-5AC1-4EC1-B7CE-4565F89B5114Q34395031-80F23FC1-12C9-47ED-914F-C26D983ADAB8Q34510205-47B0C38B-3882-429F-8846-21393BE4894FQ34958178-E7884303-EC6B-4BDD-811D-B557439EB210Q35003657-74565A2C-1915-402A-AF8B-6765E760BE15Q35683831-068C9B53-7EB1-447A-A9C2-F9A1EF1DBFA0Q36301182-091BC5B2-04F6-4C54-BC8E-A57340F7C6B3Q36379340-E2B39C4C-67D7-4E85-B360-126B0944C3D4Q36394825-A5303B6E-BB98-42A2-B4A2-53D9C41D1446Q36571570-0E7671E2-3716-4AB4-9507-D24C290A2CD6Q36621938-6F85EF64-DB1B-441C-93EE-C949BE8775D8Q36674393-1CDE1DDC-BD6B-48F3-84D0-A506461AA9BFQ37170927-BE97879C-ED4C-437F-8FB2-BA3D70A6921AQ37200466-5CBFC387-E2E0-47F8-B3EF-5F33E01CEEDDQ37242496-21624F32-B948-47AB-BE86-5ED34B1282DFQ37253554-FBE0CCAB-C678-4185-90BD-DAF13F26BB92Q37287032-71858811-FB2D-48B3-BC19-CED6149B4AACQ38097867-9608310A-279B-4921-8BAB-FD5D436D7140Q38111388-0979380D-4465-4E9C-A4A3-7CD4C6D859FFQ39606523-E96F6DA0-0802-4EF1-9EB6-74072871D836Q40381466-95DE9D52-C2F5-4609-ACFD-55821D982AF8Q40803071-3433F88B-4317-44C0-B882-45FC87411953Q40840344-A678A1C1-D687-4C8C-BE10-0869614D991BQ42323574-668F40DC-79F0-4C46-9374-314DD2FE063DQ47128290-4A50C2D5-44E2-4982-B726-DF08F44EFD21
P2860
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
name
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@ast
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@en
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@nl
type
label
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@ast
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@en
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@nl
prefLabel
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@ast
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@en
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@nl
P2093
P1476
FR901228, a novel antitumor bi ...... n experimental tumors in mice.
@en
P2093
Kawamura I
Matsumoto S
Mukumoto S
Nishigaki F
Shimomura K
P304
P577
1994-03-01T00:00:00Z